Literature DB >> 18829473

Statistical issues in translational cancer research.

Stephen L George1.   

Abstract

The explosion of knowledge about the basic biological processes and the genetics of cancer has led to increasing optimism that this knowledge can be put to practical clinical use in the near future. Indeed, important examples of translational approaches can already be found in the areas of drug discovery and development, disease diagnosis and classification, selection of therapeutic regimens for individual patients, and designing clinical trials. These are important developments but, as with any new approach, there is a danger of unwarranted enthusiasm and premature clinical application of laboratory results based on insufficient evidence. To carry out the translation of knowledge into practice with maximal efficiency and effectiveness, it is essential to conduct studies with appropriate designs and analyses based on sound statistical principles. This article provides an overview of some of these principles applied to assay development, validation of predictive models, and the design of clinical trials for targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829473     DOI: 10.1158/1078-0432.CCR-07-4537

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  20 in total

Review 1.  DNA repair and personalized breast cancer therapy.

Authors:  Shu-Xia Li; Ashley Sjolund; Lyndsay Harris; Joann B Sweasy
Journal:  Environ Mol Mutagen       Date:  2010 Oct-Dec       Impact factor: 3.216

2.  Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint.

Authors:  Stefan Michiels; Richard F Potthoff; Stephen L George
Journal:  Stat Med       Date:  2011-02-23       Impact factor: 2.373

3.  Assessing treatment-selection markers using a potential outcomes framework.

Authors:  Ying Huang; Peter B Gilbert; Holly Janes
Journal:  Biometrics       Date:  2012-02-02       Impact factor: 2.571

4.  Designing a study to evaluate the benefit of a biomarker for selecting patient treatment.

Authors:  Holly Janes; Marshall D Brown; Margaret S Pepe
Journal:  Stat Med       Date:  2015-06-25       Impact factor: 2.373

Review 5.  Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.

Authors:  Miranta Antoniou; Ruwanthi Kolamunnage-Dona; Andrea L Jorgensen
Journal:  J Pers Med       Date:  2017-01-25

Review 6.  Genomic markers for decision making: what is preventing us from using markers?

Authors:  Vicky M Coyle; Patrick G Johnston
Journal:  Nat Rev Clin Oncol       Date:  2009-12-15       Impact factor: 66.675

Review 7.  Validation of analytic methods for biomarkers used in drug development.

Authors:  Cindy H Chau; Olivier Rixe; Howard McLeod; William D Figg
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

Review 8.  Institutional shared resources and translational cancer research.

Authors:  Paolo De Paoli
Journal:  J Transl Med       Date:  2009-06-29       Impact factor: 5.531

9.  Avoiding Pitfalls in the Statistical Analysis of Heterogeneous Tumors.

Authors:  David E Axelrod; Naomi Miller; Judith-Anne W Chapman
Journal:  Biomed Inform Insights       Date:  2009-01-01

10.  A framework for evaluating markers used to select patient treatment.

Authors:  Holly Janes; Margaret S Pepe; Ying Huang
Journal:  Med Decis Making       Date:  2013-06-27       Impact factor: 2.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.